Conclusion During sleep lung mucociliary clearance in stable asthma was reduced, which is in agreement with the group's previous findings. Treatment with controlled/slow release oral bronchodilators had no effect on this reduced rate of clearance associated with sleep. (Thorax 1993;48:287-289) Lung mucociliary clearance, one of the lung's host defence clearance mechanisms, is impaired in patients with airways disease.1-4 Furthermore, lung mucociliary clearance has been shown to be reduced during sleep in healthy subjects5 and in patients with asthma,6 and this may contribute to the mucus plugging which is known to be present in the small airways of asthma sufferers.7
Methods

PATIENTS
Twelve patients with asthma, six of whom were male, volunteered for the study. Three (two female) were withdrawn, two because of an exacerbation of their asthma (one during the run in period and the other during the salbutamol period), and the third because he was unable to manage without an oral bronchodilator during the run in period.
The patients who completed the study had a mean(SE) age of 65(5) years, percentage predicted FEV, of 61(9)% and a tobacco consumption of 12(5) pack years (seven exsmokers and two non-smokers). Seven patients were receiving treatment with inhaled /32 agonists and corticosteroids, three of whom were taking inhaled anticholinergic drugs. One other patient was receiving inhaled sodium cromoglycate only. The ninth patient was on no medication. Five of the patients were also receiving treatment with oral bronchodilators (four methylxanthines and one a /32 agonist), which were discontinued for the one week run in period and for the duration of the trial. All nine patients had shown a 15% or greater reversibility of FEV, following the inhalation of 200 ,ug salbutamol (n = 5), or a 20% or greater difference between the maximum and minimum peak expiratory flows (PEF) obtained for that day on at least two days where the PEF had been measured on seven consecutive days (n = 6), or both.
STUDY DESIGN Salbutamol (8 mg twice daily), theophylline (350 mg twice daily) and placebo tablets were compared in a double blind, randomised, crossover study of seven weeks' duration. Patients underwent a one week run in period followed by three treatment periods, each of two weeks, which were not separated by wash out periods. Although the study design was such that the three treatment periods followed one another immediately, in practice this was not always possible because of previous commitments by the patients, or exacerbation of their asthma, or both. Those who had an exacerbation did not proceed into the next leg of the study until one month after the end of symptoms, or cessation of any oral corticosteroid treatment, or both. The patients were allowed to take their regular treatment throughout the study. The compliance with test medication was assessed by issuing a known number of tablets and counting those returned at the end of each treatment period. The last tablet was taken after the inhalation of radioaerosol, before sleep, and under supervision.
Informed written consent was obtained from each patient and the study was approved by the hospital's ethical subcommittee. and expressed in terms of a penetration index. '5 During the observation period any sputum samples produced were collected and weighed and their radioactive content measured.
PULMONARY ]FUNCTION
The FEVy for each patient was measured with a Vitalograph spirometer at the start of the study and during the half hour which preceded the inhalation of the radioaerosol on each study night. Predicted values were obtained on the basis of the patient's sex, age and height. 16 
STATISTICAL ANALYSIS
The data were analysed with the Wilcoxon signed rank sum test for matched pairs.'7 The level of significance was taken at p < 0 05.
Results
The mean(SE) rates of compliance with trial medication were 99 (2)%, 98 (1)%, and 98 (3)% for placebo, theophylline, and salbutamol, respectively. Usage of other medication remained unchanged during the three periods. The mean (SE) alveolar deposition rates (18 (4)%, 26 (6)%, and 27 (6)%, respectively for placebo, theophylline, and salbutamol) and the mean (SE) penetration indices (0X29 (006), 0 38 (0X10), and 0X42 (0 12) respectively for placebo, theophylline and salbutamol) for the patients following the three treatments were similar. The percentage predicted FEVy values measured at the laboratory for each treatment were 53 (7)%, 55 (8)%, and 60 (9)% respectively for placebo, theophylline, and salbutamol (p < 0.05 for salbutamol v placebo).
The mean (SE) durations of the observation periods before, during, and after sleep following radioaerosol inhalation were 23(5), 350 (9) , 38 (6); 18 (3), 342 (8) , 36 (7); and 22 (3) , 357 (8) , 38 (8) minutes respectively for placebo, theophylline and salbutamol. The rates of clearance for the periods before, during and after sleep following the three treatments are shown in the figure. There were no significant differences in the rates of radioaerosol clearance from the lungs between the three treatments for the three periods. Within each of the three treatments the rate of clearance during sleep was significantly lower than the rates before and after sleep (p < 0-01).
Only one patient produced sputum during the observation period (placebo: 3-6 g containing 15% of the initial tracheobronchial deposition; theophylline: 2-0 g containing 31% of the initial tracheobronchial deposition).
Discussion
The rate of tracheobronchial clearance of deposited radioaerosol depends on its site of deposition within the lungs.'" In this study alveolar deposition and the penetration index 
